ADBiotech Co., Ltd. (KOSDAQ:179530)
South Korea · Delayed Price · Currency is KRW 1,835.00
+5.00 (0.27%)
At close: Jan 23, 2026
ADBiotech Revenue
ADBiotech had revenue of 3.63B KRW in the quarter ending September 30, 2025, with 109.35% growth. This brings the company's revenue in the last twelve months to 14.57B, up 65.55% year-over-year. In the year 2024, ADBiotech had annual revenue of 11.14B with 6.34% growth.
Revenue (ttm)
14.57B
Revenue Growth
+65.55%
P/S Ratio
2.29
Revenue / Employee
n/a
Employees
n/a
Market Cap
33.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.14B | 664.30M | 6.34% |
| Dec 31, 2023 | 10.47B | -159.63M | -1.50% |
| Dec 31, 2022 | 10.63B | -1.21B | -10.21% |
| Dec 31, 2021 | 11.84B | 2.02B | 20.63% |
| Dec 31, 2020 | 9.82B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 31.12B |
| Eutilex.Co.,Ltd | 10.54B |
| NGeneBio | 9.98B |
| MOA Life Plus | 9.80B |
| SCM Lifescience | 1.54B |
| Aptamer Sciences | 1.08B |
| Kainos Medicine | 938.87M |
| Epibiotech | 449.62M |